AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05057754 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooking
Description: Participants will be asked to participate in a cooking trial following a prespecified cooking recipe of Rice Krispy Treat. he participant will be asked to follow the procedures as follows: (1) cut and put wax paper in the pan; (2) cut butter into 4 pieces; (3) place butter in a pot over a portable stove and stir until the butter is completely melted; (4) add four oz of marshmallows and stir until melted; (5) add cereal and the rest of marshmallows and stir until all ingredients are combined (6) transfer the ingredients to the pan and use a silicone spatula to pat the ingredients evenly into pan.
Study NCT05868499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EXG34217
Description: Single infusion
Study NCT05015972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTA30X UCAR-T injection
Description: CTA30X UCAR-T injection is an allogeneic CAR-Ttargeted CD19 . A single infusion of CART cells will be administered intravenously.
Study NCT05574998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin (Endostar)
Description: The specific treatment regimen is as follows: Non-squamous NSCLC: Endostar (210 mg, CIV for 120 h) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) +pemetrexed 500 mg/m2 (d4) Q3W is administered in this regimen for 4 cycles followed by Endostar plus pemetrexed until disease progression or intolerable toxicity.~Squamous NSCLC: Endostar (210 mg, CIV for 120 hours) is started on the first day of each treatment cycle and administered every three weeks. Carboplatin AUC 5-6 mg/ml/min or cisplatin 75 mg/m2 (d4) + paclitaxel 175 mg/m2 (d4) Q3W.Endostar is administered after 4 cycles of this treatment regimen until disease progression or intolerable toxicity developed.
Study NCT04938817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: coformulation pembrolizumab/quavonlimab
Description: Intravenous (IV) infusion
Study NCT04938817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Oral administration
Study NCT04938817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-4830
Description: IV infusion
Study NCT04938817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: coformulation favezelimab/pembrolizumab
Description: IV infusion
Study NCT04938817 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R-DXd
Description: IV Infusion
Study NCT06339905 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonic Activation with EndoActivator
Description: sonic activation
Study NCT06339905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Needle Irrigation
Description: control group
Study NCT06561932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WiSE CRT System
Description: The WiSE CRT System is an implantable cardiac system to provide left ventricular (LV) pacing stimulation in conjunction with a co-implanted system that provides right ventricular (RV) stimulation. In combination, the devices deliver biventricular (BiV) pacing.
Study NCT06312722 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optilume® BPH Catheter System
Description: The Optilume BPH Catheter System is a combination drug/device minimally invasive surgical therapy (MIST) comprised of an uncoated pre-dilation balloon catheter and a separate drug coated balloon (DCB) catheter. The distal end of each catheter has a semi-compliant, inflatable, double lobe balloon that is used to dilate the prostate. The double-lobe DCB catheter is coated with a proprietary coating containing the active pharmaceutical agent paclitaxel. The drug coating covers the working length of the balloon body.
Study NCT05540990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted gait training
Description: 15 sessions of robot-assisted gait training (two times per week with a maximum of 45 minute each).
Study NCT05540990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
Study NCT05540990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy
Description: individually customized to the needs of the child and usually consists of 2-3 sessions of physiotherapy per week.
Study NCT05636826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atherolive-drug
Description: The patient will be assigned to one of two treatments (atherolive ) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
Study NCT05636826 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Atherolive
Description: The patient will be assigned to one of two treatments using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. Placebo will be prescribed at a dose of 400 mg, once a day for 3 months.
Study NCT06122116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: The PT treatment participants receive in this study will be standard of care; that is, the PT treatment regimen will not be standardized across study participants and/or dictated by study-specific criteria. Participants will be referred to the Physical Therapy Department at the Madigan Army Medical Center (MAMC). Number of PT treatments will be documented on a follow-up Chart Review.
Study NCT06122116 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Plasma Injection
Description: PRP injection procedures will follow current clinical recommendation and standard operating procedures. Prior to the injection, the area will be sterilely prepared and anesthetized with either ethyl chloride spray or lidocaine (limited to the cutaneous and subcutaneous layer, so as not to alter the synovial contents). Then, the participant will receive LP-PRP injection in the affected knee area under ultrasound guidance. Qualified study providers will inject 2-5cc LP-PRP using an 18-gauge 1/5-inch needle for both aspiration and subsequent injection. Study providers will select the injection portal they are most comfortable with, in order to achieve an accurate intra-articular injection. The PRP injection procedure is expected to take approximately one hour.
Study NCT06122116 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation Therapy
Description: PBMT is delivered with the LightForce® XPi 25W device through the Smart Hand Piece technology. PBMT will be delivered at 6 J/cm\^2 and applied in a circular pattern to the knee area.
Study NCT02811133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inositol
Description: Subjects will receive inositol
Study NCT05120817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal intervention
Description: Participants will receive a link with an invitation to watch a 10-minute educational video about the personal benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
Study NCT05120817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social intervention
Description: Participants will receive a link with an invitation to watch a 10-minute educational video about the social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
Study NCT05120817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal + Social intervention
Description: Participants will receive a link with an invitation to watch a 10-minute educational video about both personal and social benefits and costs of vaccination against COVID-19. They will also go through pre-and post-test data collection.
Study NCT06035432 — intervention group
Intervention type: OTHER
Intervention: Bluesky software
Description: Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Bluesky software.
Study NCT06035432 — intervention group
Intervention type: OTHER
Intervention: 3D slicer software
Description: Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by 3D slicer software.
Study NCT06035432 — intervention group
Intervention type: OTHER
Intervention: OnDemand software
Description: Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by OnDemand software.
Study NCT06035432 — intervention group
Intervention type: OTHER
Intervention: Mimics software
Description: Dental stone casts will be scanned with a desktop scanner and then STL files will be exported. Virtual 3D surface models will be obtained by Mimics software.
Study NCT05858736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI-061
Description: A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
Study NCT05948033 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70-targeting CAR-T cells
Description: Dose escalation:~Dose1 (1×10\^6 cells/kg) ,Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7 cells/kg)~Doseexpansion: RP2D~Drug: Fludarabine~Intravenous fludarabine 25-30 mg/m\^2/day on days 5, -4, and -3.~Drug: Cyclophosphamide~Intravenous cyclophosphamide 300-500 mg/m\^2/day on days -5, -4, and -3.
Study NCT06444165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lebrikizumab Pen
Description: Injected into a practice pad.
Study NCT05293002 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restorer Iliac Stent System
Description: Not applicable (only one intervention)
Study NCT05818930 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: REMI
Description: Diagnostic monitoring
Study NCT05730764 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Accurate prediction of fertilization disorders and clinical decision support systems assist doctors in decision-making
Description: With the assistance of accurate prediction of fertilization disorders and clinical decision support systems, clinicians predict and judge the probability and key factors of fertilization disorders of patients, and formulate and implement personalized diagnosis and treatment plans based on the prediction results
Study NCT05730764 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Clinicians follow a routine protocol
Description: Treatment is performed by the clinician according to the usual protocol.
Study NCT06271538 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Skal Pro
Description: One sachet Skal Pro per day containing Lactobacillus plantarum 299v 1x10\^10 CFU and GOS
Study NCT04648046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Non-ablative conditioning with cyclophosphamide.
Study NCT04648046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVgp120duoCAR-T cells, low dose
Description: A single dose of 3 x 10\^5 cells/kg LVgp120duoCAR-T cells will be infused.
Study NCT04648046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LVgp120duoCAR-T cells, high dose
Description: A single dose of 1 x 10\^6 cells/kg LVgp120duoCAR-T cells will be infused.
Study NCT05291351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crackers made with whole, coarse, or fine pea and/or wheat flour
Description: Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
Study NCT05291351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Crackers made with whole, coarse, or fine lentil and/or wheat flour
Description: Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
Study NCT06271538 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One sachet per day identical in shape, size, colour, packaging and taste to the Skal Pro sachet
Study NCT06101563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early ureteroscopy
Description: Patients will be managed by ureteroscopic lithotripsy 7 days after drainage.
Study NCT06101563 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Ureteroscopy
Description: Patients will be managed by ureteroscopic lithotripsy 14-21 days after drainage.
Study NCT04648046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analytic Treatment Interruption
Description: HIV antiretroviral therapy medications will be paused.
Study NCT04088188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT04088188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT04088188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO
Study NCT04088188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Given PO
Study NCT05211986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IMM01-STEM
Description: IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
Study NCT06226987 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga-DOTATATE PET/MRI
Description: PET/MRI scanning
Study NCT06302543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous bone marrow cells injection
Description: under general anesthesia bone marrow aspiration done followed by cell concentration and transvaginal ovarian injection
Study NCT05733390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP541
Description: Oral suspension
Study NCT05733390 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral suspension
Study NCT05966792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Description: Sodium-glucose cotransporters inhibitors (SGLT2i) are novel hypoglycemic drugs with unique hypoglycemic mechanisms, which are completely independent of islet β-cell function or insulin sensitivity. Previous studies have shown that SGLT2i may improve IR by inhibiting glucotoxicity, reducing body weight, reducing inflammation, improving islet β-cell function, and reducing oxidative stress.
Study NCT05966792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metformin
Description: Metformin is a classic drug for the treatment of polycystic ovary syndrome, which can improve the degree of insulin resistance in PCOS patients.
Study NCT04871282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL102
Description: AL102 is an inhibitor of gamma secretase-mediated Notch signaling.
Study NCT04871282 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AL102
Study NCT05291351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Porridge made with oat flour
Description: Participants will consume 1 of the 4 treatments at each of 4 study sessions in random orders such that by the end of the study, they will have consumed all 4 treatments. They will be given 10 minutes to consume the entire treatment with a glass of water.
Study NCT05255666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg intravenously
Study NCT05255666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Starting at 50 mg/m\^2. The dose may be increased to 70 mg/m\^2 if tolerated or dose reduced to 35 mg/m\^ if treatment-emergent severe adverse event (TESAE) occurs.
Study NCT06041802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3475A
Description: MK-3475A is a fixed-dose formulation of pembrolizumab and MK-5180 for SC administration.
Study NCT06466473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin (Ascoli)
Description: Phenytoin 50mg chewable tablets
Study NCT06466473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin (Vega Baja)
Description: Phenytoin 50mg chewable tablets
Study NCT06536036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0270
Description: Use according to the prescribed protocol
Study NCT06640621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Different concentration of ropivacaine for single brachial plexus block
Description: 40 ASA grade I - II patients were selected from the patients who underwent shoulder ligament rupture repair surgery under selective general anesthesia combined with brachial plexus block analgesia in the sports medical center of our hospital. They were randomly divided into two groups: high concentration group (group I) and low concentration group (Group II), with 20 cases in each group. 40 patients underwent a single brachial plexus block under ultrasound guidance before general anesthesia.
Study NCT06640621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Different concentration of ropivacaine for single brachial plexus block
Description: 40 ASA grade I - II patients were selected from the patients who underwent shoulder ligament rupture repair surgery under selective general anesthesia combined with brachial plexus block analgesia in the sports medical center of our hospital. They were randomly divided into two groups: high concentration group (group I) and low concentration group (Group II), with 20 cases in each group. 40 patients underwent a single brachial plexus block under ultrasound guidance before general anesthesia.
Study NCT06638489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity-Focused-Electromagnetic-Therapy (HIFEM)
Description: The HIFEM stimulation was administered using an Emsella instrument (manufactured by BTL Industry Inc., Boston, MA). The frequency ranged between 50 and 60Hz, and the intensity was as high as the patient could tolerate, which was usually up to 100%.
Study NCT06638489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic-Floor-Muscle-Training (PFMT)
Description: The PFMT protocol was that outlined by previous study. The participants were instructed to execute 5 rapid contractions over a span of 3 seconds and 10 prolonged contractions, each lasting between 3 to 8 seconds, with intervals of 10 seconds for relaxation in between, all while in a crook-lying position.
Study NCT06642766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber supplement
Description: Subjects that meet the inclusion criteria and with symptoms appropriate for fiber supplementation are eligible to participate. Participants will be instructed to use the fiber product (NutraLieve) as currently labeled; start with a dosage of 4-5 grams per day (one heaping teaspoon), initially taken once daily, increasing up to 3 heaping teaspoons a day (maximum dose 15 grams/day) on an as needed basis.Participants will be prospectively assessed for symptoms at baseline and at 6 weeks.~* The primary endpoint, number of bowel movements, will be assessed by bowel movements in the last 72-hour period at baseline and at 6 weeks, by patient recall/diary.~* Secondary endpoints, reduction in bloating or gas, or any adverse events will be assessed using analog scales, also by 72-hour recall at baseline and at 6 weeks, by patient recall/diary.
Study NCT06639893 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telescopic overdenture
Description: Telescopic overdenture with two dental implants in intraforaminal area for mandible.
Study NCT06639893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Telescopic overdenture
Description: Telescopic overdenture with two dental implants in intraforaminal area for mandible.
Study NCT06642038 — intervention group
Intervention type: PROCEDURE
Intervention: Transbronchial Endoscopic Thermal Vapor Ablation
Description: Transbronchial Endoscopic Thermal Vapor Ablation
Study NCT05231915 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: HOXB13 c.853delT mutation
Description: Identify the Allelic frequency of the HOXB13 c.853delT mutation in patients with a cancer prostate in Martinique
Study NCT06639230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser therapy
Description: Laser-treated group (test group): This group consisted of ten patients treated using diode lasers. The diode laser was operated in continuous wave mode with an output power of 3 W in contact mode to excise the pyogenic granuloma. The tip was moved around the base of the lesion in circles. The base of the lesion was cut precisely till the whole mass was entirely excised.
Study NCT06639230 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Sclerotherapy-treated group (control group): This group consisted of ten patients treated with injections of sclerosing agent. After anaesthetizing the surgical site with a local anesthetic agent, The lesion was injected with a 2.5% concentration until it leaked out from the surface, leading to necrosis and spontaneous detachment of the lesion.
Study NCT06642597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental PD
Description: Incremental PD: Commence PD using goal-directed PD prescription ≤14 exchanges/week for continuous ambulatory PD (CAPD) or ≤21 exchanges/week for automated PD (APD) with no day dwell until an indication for increase in the PD dose (trigger point) is reached.